BYSI - BeyondSpring EPS misses by $0.17

BeyondSpring (BYSI): FY GAAP EPS of -$2.03 misses by $0.17.Revenue of $180K.CEO comment: “The Company is well positioned for the future, with our “pipeline in a drug” plinabulin, and anticipated near-term potential anti-cancer efficacy data from a Phase 3 trial measuring overall survival in NSCLC, and from early trials in several immuno-oncology regimens in checkpoint inhibitor naïve or failed patients. After the successful completion of our equity financing in the fourth quarter, we have strengthened our balance sheet and cash position as we head into our upcoming milestones.”Press Release

For further details see:

BeyondSpring EPS misses by $0.17